Enobosarm (VERU-024, ostarine, GTx-024, MK-2866)
Prevention of muscle loss and augmentation of fat loss in sarcopenic obese/overweight patients receiving GLP-1 RA therapy for weight management
Key Facts
About Veru
Veru Inc. is a biopharmaceutical company targeting significant unmet needs in cardiometabolic and inflammatory diseases with its two lead clinical candidates. The company is strategically positioning enobosarm as a combination therapy to address the muscle-wasting side effect of popular GLP-1 receptor agonists for weight loss, aiming to improve the quality of weight reduction. Concurrently, it is developing sabizabulin to target the inflammatory drivers of atherosclerosis. Veru operates as a public company and is led by a management team with extensive experience in drug development and commercialization.
View full company profile